CRGT - cortigent.com Debt to Book Capitalization Ratio

Total debt relative to book capitalization demonstrates the financial stability of Cortigent, Inc., with the value of reflecting this status. Cortigent, Inc. implements neural interfaces to restore lost sensory and motor functions. The business creates implants for the blind and paralyzed, operating in the growing BCI segment. High medical standards and patent protection ensure a robust market moat.

Cortigent (CRGT) - Debts to Book Value from 07/04/2022 to 10/27/2026

This ratio reflects the proportion of borrowed funds relative to equity, determining financial stability and the level of leverage. For Cortigent, Inc. (CRGT), the degree to which balance sheet capital covers debt obligations demonstrates the company's ability to fund the development of neurostimulators without a critical debt burden. An optimal balance of this metric prevents resource stagnation while maintaining protection against market shocks. It is crucial for investors to see moderate leverage dynamics to ensure the expansion of brain-computer interfaces. Low values minimize bankruptcy risk but may signal an underutilization of capital for accelerated growth.

Competitors of Cortigent, Inc.

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|Debts to Book Capitalization VKTX|Debt to Book Value SUPN|Catalyst Pharmaceuticals, Inc. - Debt to Book Capitalization Ratio|Debts to Book Value DNLI (Denali)|Debt to Book Capitalization Ratio Harmony Pharma|BHVN - Debt to Net Assets Ratio|Debt to Book Value Amylyx Pharmaceuticals AMLX|TRVI - Debt to Book Capital|Praxis Precision Medicines, Inc. - Debts to Book Capitalization|Anavex (AVXL) - Debts to Net Assets|CeriBell Corp - Debts to Book Capitalization|Debt to Net Assets prothena.com|Alector, Inc. - Debts to Book Capitalization|Debts to Book Value ANNX (annexonbio.com)|OMER - Debt to Book Capitalization Ratio|NGNE - Debt to Book Value Ratio|Debt to Book Value AC Immune Corp ACIU|Voyager Corp (VYGR) - Debt to Book Capital|Debt to Book Value Neumora Therapeutics NMRA|scilexholding.com (SCLX) - Debt to Net Assets Ratio|TVGN: Debts to Book Capitalization|Debts to Net Assets ACOG|Debt to Book Capitalization Ratio Cognition Therapeutics CGTX|Debt to Book Value Ratio Inhibikase Pharma (IKT)|Cassava Sciences, Inc. - Debts to Book Capitalization|ASRT - Debt to Book Value|Debt to Book Value COYA (Coya)|VTGN - Debts to Net Assets|OVID (ovidrx.com) - Debts to Book Capitalization|ABOS (Acumen Pharmaceuticals, Inc) - Debt to Book Value|CRVO - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Alterity Therapeutics Ltd|CLNN: Debts to Book Capitalization|Debt to Net Assets pepgen.com PEPG|Debt to Book Value Jupiter Neurosciences Inc (JUNS)|Relmada Corp - Debt to Book Capital|Annovis Bio, Inc. (ANVS) - Debt to Book Capitalization Ratio|GRCE - Debt to Book Value Ratio|Debts to Book Capitalization AIFF|Debts to Book Value Klotho Neurosciences|NRSN (NeuroSense Therapeutics Ltd) - Debt to Book Value|Debts to Book Capitalization RVPH|MetaVia Inc (MTVA) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio NRXS (neuraxis.com)|HSDT: Debt to Book Capitalization Ratio|Debts to Book Value Passage Bio Inc. PASG|NEUP: Debts to Book Capitalization|NERV: Debt to Book Value|Debt to Book Capitalization Ratio ATHA|ADXN (addextherapeutics.com) - Debts to Book Value|ALZN - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Cyclerion (CYCN)|Debt to Book Value Protagenic Therapeutics|Debt to Book Capital pasitheaclinics.com (KTTA)|Debts to Book Capitalization ATXI|Debts to Net Assets brainstorm-cell.com BCLI|Debts to Book Capitalization CARA|CHRO - Debt to Net Assets|Debts to Book Capitalization ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debts to Book Value|Debt to Book Capitalization Ratio Longboard Pharmaceuticals (LBPH)|Debt to Book Value Ratio marinuspharma.com (MRNS)|Debt to Book Value NKGen Biotech|Debt to Book Capital NeuroBo Pharmaceuticals Inc NRBO|Debt to Book Value Sage Therapeutics, Inc|Debt to Net Assets Ratio Synaptogenix, Inc SNPX|Debts to Book Capitalization TRVN (Trevena, Inc.)|VIGL: Debts to Net Assets|Debt to Book Capitalization Ratio Anew Medical|Cerevel Therapeutics Inc (CERE) - Debt to Book Value Ratio